To hear about similar clinical trials, please enter your email below
Trial Title:
ComCancer: Use of Let's Discuss Health Website by Patients With Prostate Cancer Undergoing Radiation Oncology Treatment
NCT ID:
NCT05787145
Condition:
Prostatic Neoplasms
Psychological Distress
Physician-Patient Relations
Communication
Patient Participation
Adherence, Treatment
Men
Conditions: Official terms:
Prostatic Neoplasms
Conditions: Keywords:
Prostate Cancer
Patient-Physician Communication
Patient Recall of Information
Adult
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Intervention model description:
Comparative study in which two distinct groups of patients will be formed, sequentially.
Patients from both groups will be assessed by the same radiation oncologists recruited
from each of the three centers. In each center, recruited patients will initially be
assigned to Group 1 (Usual Care) until 50 patients will be included in the study (for a
total of 150 patients in this group). Recruitment will then pursue and patients will be
assigned to Group 2 (Intervention) until 50 patients will be included in the study (for a
total of 150 patients in this group).
Patients in Group 1 (Usual Care) will be assessed during regular consultations of the
radiation oncology care pathway. Those in Group 2 (Intervention) will be encouraged to
prepare each of the four medical encounters targeted in the usual trajectory in radiation
oncology using Let's Discuss Health website. For Group 2, the radiation oncologists will
have participated in an workshop on the Let's Discuss Health website.
Primary purpose:
Other
Masking:
None (Open Label)
Intervention:
Intervention type:
Behavioral
Intervention name:
Let's Discuss Health Group
Description:
Use of the Let's Discuss Health website to prepare four medical encounters with the
radiation oncologist throughout the radiation care trajectory.
Arm group label:
Let's Discuss Health Group
Other name:
Pre-consultation patient's preparedness
Summary:
In Canada, the prevalence of cancer is growing and contributes significantly to health
costs. The prevention and treatment of cancer is a major concern of our health system.
Many men with prostate cancer develop psychological distress. The emotional consequences
of a cancer diagnosis and its treatments can prevent patients from communicating
effectively with their healthcare team. It is recognized that the quality of
communication between cancer patients and their caregivers plays an important role in the
management of their disease. However, few tools are being developed to help clinicians
and patients better communicate and decrease patients' psychological distress. Let's
Discuss Health (www.discutonssante.ca) is a French-language website that offers several
tools to support collaboration between caregivers and cancer patients.
The objectives of this research project are to assess the experience of using the Let's
Discuss Health website and the impact of its use on the quality of communication between
radiation oncologists and patients, the level of distress of patients with prostate
cancer, recall of the information discussed as well as adherence to the trajectory in
radiation oncology.
The project will take place in three radiation oncology centers in Quebec. Two groups of
prostate cancer patients will be recruited. Patients in the first group will be assessed
on the basis of regular consultations and those in the second group will be encouraged to
prepare for their medical visits using the Let's Discuss Health website. Patients and
their caregivers will answer short questionnaires before and after four targeted
consultations (initial visit, mid-treatment visit, end-of-treatment visit and 3-month
post-treatment visit). Focus groups will also be organized to explore the impact of the
website.
This project offers the potential to transform clinical practices in radiation oncology
to reduce the burden of cancer and improve the quality of care offered to patients with
cancer.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- have a diagnosis of prostate cancer
- understand, speak and read French
- report being comfortable using the Internet
- have access to a computer, tablet or smartphone or know someone who does and is
willing to accompany them
Exclusion Criteria:
- being considered unfit to give free and informed consent (e.g. dementia, severe
psychiatric condition)
- any other clinical reason (poor health of the patient at the time of the
consultation) that the clinician deems relevant
Gender:
Male
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Centre intégré de cancérologie de Laval
Address:
City:
Laval
Zip:
H7M 3L9
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Marie-Eve Lavoie, PhD
Phone:
514-966-4615
Email:
marie.eve.lavoie.cissslav@ssss.gouv.qc.ca
Investigator:
Last name:
Marie-Andrée Fortin, MD
Email:
Principal Investigator
Investigator:
Last name:
Moein Alizadeh, MD
Email:
Sub-Investigator
Facility:
Name:
Ciusss de l'Est de l'Île de Montréal
Address:
City:
Montréal
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Marie-Eve Lavoie, PhD
Phone:
514-966-4615
Email:
marie.eve.lavoie.cissslav@ssss.gouv.qc.ca
Investigator:
Last name:
Israël Fortin, MD
Email:
Principal Investigator
Facility:
Name:
Centre hospitalier universitaire de Québec
Address:
City:
Québec
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Marie-Eve Lavoie, PhD
Phone:
514-966-4615
Email:
marie.eve.lavoie.cissslav@ssss.gouv.qc.ca
Investigator:
Last name:
William Foster, MD
Email:
Principal Investigator
Investigator:
Last name:
Isabelle Germain, MD
Email:
Sub-Investigator
Start date:
March 10, 2021
Completion date:
November 2024
Lead sponsor:
Agency:
Ciusss de L'Est de l'Île de Montréal
Agency class:
Other
Collaborator:
Agency:
Hopital Cité de la Santé
Agency class:
Other
Collaborator:
Agency:
CHU de Quebec-Universite Laval
Agency class:
Other
Source:
Ciusss de L'Est de l'Île de Montréal
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05787145
